Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
MT Newswires Live
Oct 07
Fractyl Health (GUTS) said Tuesday that new preclinical data from its obesity candidate RJVA-002 showed 30% weight loss in mice after a single dose, with no adverse effects observed.
The company said the study used a diet-induced obesity model with humanized GIP receptors and demonstrated a dose-dependent reduction in body weight over five weeks, with weight loss still ongoing.
RJVA-002, the second candidate from its Rejuva Smart GLP-1 platform, expands its potential use from type 2 diabetes to obesity, the company said. It said RJVA-001 is set to begin human trials next year for type 2 diabetes.
Shares of the company were up less than 1% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.